Press Release – New York, NY – April 1, 2025 – Sichenzia Ross Ference Carmel LLP announced today that it represented Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, in its $3.9 million registered direct offering and concurrent private placement.
The SRFC team was led by partner Jay Yamamoto and associate Rohini Sud.
